PH25587A - Mixed crystals of insulin, insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals,, theu use thereof for the treatment of diabetes mellitus - Google Patents

Mixed crystals of insulin, insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals,, theu use thereof for the treatment of diabetes mellitus

Info

Publication number
PH25587A
PH25587A PH36954A PH36954A PH25587A PH 25587 A PH25587 A PH 25587A PH 36954 A PH36954 A PH 36954A PH 36954 A PH36954 A PH 36954A PH 25587 A PH25587 A PH 25587A
Authority
PH
Philippines
Prior art keywords
mixed crystals
insulin
treatment
diabetes mellitus
theu
Prior art date
Application number
PH36954A
Other languages
English (en)
Inventor
Michael Dorschug
Rainer Obermeier
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PH25587A publication Critical patent/PH25587A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
PH36954A 1987-05-22 1988-05-20 Mixed crystals of insulin, insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals,, theu use thereof for the treatment of diabetes mellitus PH25587A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873717370 DE3717370A1 (de) 1987-05-22 1987-05-22 Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus

Publications (1)

Publication Number Publication Date
PH25587A true PH25587A (en) 1991-08-08

Family

ID=6328227

Family Applications (1)

Application Number Title Priority Date Filing Date
PH36954A PH25587A (en) 1987-05-22 1988-05-20 Mixed crystals of insulin, insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals,, theu use thereof for the treatment of diabetes mellitus

Country Status (20)

Country Link
US (1) US5028587A (sv)
EP (1) EP0291863B1 (sv)
JP (1) JPS63303930A (sv)
KR (1) KR880013572A (sv)
AT (1) ATE71842T1 (sv)
AU (1) AU601280B2 (sv)
CA (1) CA1335924C (sv)
DE (2) DE3717370A1 (sv)
DK (1) DK278088A (sv)
ES (1) ES2032896T3 (sv)
FI (1) FI93797C (sv)
GR (1) GR3004344T3 (sv)
HU (1) HU203840B (sv)
IE (1) IE60649B1 (sv)
IL (1) IL86452A (sv)
NO (1) NO175641C (sv)
NZ (1) NZ224715A (sv)
PH (1) PH25587A (sv)
PT (1) PT87523B (sv)
ZA (1) ZA883599B (sv)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
WO1992010284A2 (en) 1990-12-07 1992-06-25 Cnc Development, Inc. Catalytic chemical reactor
DE69221725T2 (de) * 1991-05-24 1997-12-18 Amylin Pharmaceuticals, Inc., San Diego, Calif. Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
DE19903125B4 (de) * 1999-01-27 2006-01-05 Sanofi-Aventis Deutschland Gmbh Verfahren zur Trocknung von Kristallen von Insulin oder Insulinanaloga
CN1125081C (zh) 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
BR0207422A (pt) * 2001-02-09 2005-04-19 Genentech Inc Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição
US7396936B1 (en) 2004-11-09 2008-07-08 Kemia, Inc. Modulators of calcitonin and amylin receptor activity
EP2101735A2 (en) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
WO2015084694A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
EG12098A (en) * 1974-04-13 1980-12-31 Hoechst Ag New pharmaceutical insulin preparations having antidiabetic activity and process for their manufacture
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung

Also Published As

Publication number Publication date
DK278088D0 (da) 1988-05-20
AU1648788A (en) 1988-11-24
ZA883599B (en) 1989-01-25
DE3867903D1 (de) 1992-03-05
HU203840B (en) 1991-10-28
EP0291863B1 (de) 1992-01-22
IL86452A0 (en) 1988-11-15
HUT46546A (en) 1988-11-28
EP0291863A2 (de) 1988-11-23
FI93797B (sv) 1995-02-28
NO882207L (no) 1988-11-23
NZ224715A (en) 1990-04-26
CA1335924C (en) 1995-06-13
PT87523B (pt) 1992-09-30
PT87523A (pt) 1989-05-31
ES2032896T3 (es) 1993-03-01
DE3717370A1 (de) 1988-12-01
NO882207D0 (no) 1988-05-20
FI882354A (sv) 1988-11-23
DK278088A (da) 1988-11-23
FI93797C (sv) 1995-06-12
NO175641C (no) 1994-11-09
EP0291863A3 (en) 1990-04-04
IL86452A (en) 1993-02-21
IE881522L (en) 1988-11-22
ATE71842T1 (de) 1992-02-15
JPS63303930A (ja) 1988-12-12
IE60649B1 (en) 1994-08-10
NO175641B (sv) 1994-08-01
GR3004344T3 (sv) 1993-03-31
AU601280B2 (en) 1990-09-06
KR880013572A (ko) 1988-12-21
FI882354A0 (sv) 1988-05-19
US5028587A (en) 1991-07-02

Similar Documents

Publication Publication Date Title
PH25587A (en) Mixed crystals of insulin, insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals,, theu use thereof for the treatment of diabetes mellitus
IL72469A0 (en) Novel insulin derivatives,processes for their preparation and their use,and pharmaceutical agents for the treatment of diabetes mellitus
IL82209A0 (en) Insulin preparation
HUT47575A (en) Process for production of piperasinal derivatives of purine and medical compositions containing them
HUT51138A (en) Process for production of medical composition against osteoporosis containing derivatives of imidasole /1,2-a/-piridasine or pirasine
YU101385A (en) Process for obtaining crystal calcium pseudomonate or its hydrate
IL90551A0 (en) Stable,injectable,aqueous pharmaceutical compositions for the treatment of cardiac conditions
KR900012933A (ko) 당뇨병 및 과혈당증 치료제로 유용한 화합물 및 이의 제조방법
YU222189A (en) 2-azabicyclo (2.2.1) hept-5-en-2-ocetic acid, it's derivatives and familiar compounds, process for obtaining those compounds and use for obtaining n- phosphono-methylglycine
UA8036A1 (uk) Спосіб одержання похідних тіазолу або їх кислотно-аддітивних солей
HUT46904A (en) Process for production of derivatives of 1,3,5-tritian and medical compounds containing such substances
NZ236206A (en) Preparation of 2'-methyl-4'-methylenespiro(androstadiene-17,5'(4'h)-oxazol)-3-one derivatives from pregn-5-en-20-ylideneacetamide derivatives by treatment with vilsmeier reagent or acid
YU125289A (en) Process for preparing pharmaceutic compounds with delayed effect of healing substance, for oral use, which contains new inclusion complex of nicardipine, or it's hydrochloride with beta-cyclodextrine
EG19461A (en) Process for preparing of s-substituted betathioacrylamides and their use as microbicide.
SU1840597A1 (ru) Способ получения бис-(хлороксимино)-ацетона